|
Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. |
|
|
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst) |
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb/Roche (Inst); Merck Sharpe & Dohme (Inst) |
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst) |
|
|
Honoraria - Astellas Pharma; Janssen; Janssen (I) |
Consulting or Advisory Role - Abbott Laboratories; Astellas Pharma; AstraZeneca; Bayer; ESSA; Ferring; Janssen-Cilag; Medivation; Millennium; Novartis; Pfizer; Ventana Medical Systems; Veridex |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Ferring; Ipsen; Janssen; Sanofi; Takeda; Ventana Medical Systems |
Research Funding - Arno Therapeutics (Inst); Innocrin Pharma (Inst); Janssen (Inst) |
Patents, Royalties, Other Intellectual Property - I am on The ICR rewards to inventors list of abiraterone acetate. |
Travel, Accommodations, Expenses - Abbott Laboratories; Astellas Pharma; Astellas Pharma (I); Bayer; ESSA; Ferring; Janssen; Janssen (I); Medivation; Pfizer; Ventana Medical Systems |
Other Relationship - Institute of Cancer Research |
|
|
Honoraria - Astellas Pharma (Inst); Bayer; Janssen |
Consulting or Advisory Role - AstraZeneca (Inst); Bayer; Bayer (Inst); Clovis Oncology; Daiichi Sankyo; Janssen; Janssen (Inst); MSD Oncology |
Research Funding - Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca Spain; Bayer; Ipsen; Janssen; Roche |
|
|
Honoraria - Astellas Pharma; Janssen-Cilag; Merck; Pfizer; Sanofi; Takeda |
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bayer; Janssen Oncology; Myovant Sciences; Sanofi; Tokai Pharmaceuticals |
Research Funding - Janssen-Cilag |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Janssen-Cilag; Pfizer; Roche |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; MSD Oncology; Pfizer |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Janssen (Inst); SYNLAB (Inst) |
Expert Testimony - Pfizer |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Janssen; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Genentech; Janssen; Myovant Sciences |
Research Funding - AstraZeneca (Inst); Bayer (Inst); Celgene (Inst); Ferring (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); Phosplatin Therapeutics (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TRACON Pharma (Inst) |
|
|
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen Oncology; Lilly; Novartis; Pfizer |
Research Funding - Bayer (Inst); ESSA (Inst); Janssen Oncology (Inst); Lilly (Inst); ORIC Pharmaceuticals (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics; Teon Therapeutics |
Honoraria - Janssen; Johnson and Johnson |
Consulting or Advisory Role - Fortis; Fortis; Janssen Oncology; Teon Therapeutics; Ultragenyx Pharmaceuticals |
Travel, Accommodations, Expenses - Janssen |
|
|
Consulting or Advisory Role - Janssen Oncology |
Speakers' Bureau - Astellas Pharma; Bayer; Janssen Oncology |
Research Funding - Bayer; Janssen Oncology; MSD Oncology; Roche |
|
|
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Cipla; Eisai; Ipsen; Johnson&Johnson; Novartis; Pfizer |
Consulting or Advisory Role - AstraZeneca; BMS; Johnson&Johnson; Merck; MSD; Novartis; Viatris |
Research Funding - Johnson & Johnson; MSD |
|
|
No Relationships to Disclose |
|
|
Employment - Johnson & Johnson |
Stock and Other Ownership Interests - Johnson & Johnson |
Research Funding - Johnson & Johnson |
Patents, Royalties, Other Intellectual Property - Johnson and Johnson |
Travel, Accommodations, Expenses - Johnson & Johnson |
|
|
Employment - Janssen Research & Development |
Patents, Royalties, Other Intellectual Property - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Janssen Research & Development |
Patents, Royalties, Other Intellectual Property - Janssen Research & Development |
|
|
Employment - Janssen Research & Development; Merck (I) |
Stock and Other Ownership Interests - Johnson & Johnson; Merck (I) |
Travel, Accommodations, Expenses - Janssen Research & Development |
|
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson & Johnson/Janssen |
Travel, Accommodations, Expenses - Janssen Research & Development; Janssen Research & Development |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
|
Stock and Other Ownership Interests - Janssen |
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst) |
Expert Testimony - AstraZeneca; Novartis |